Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 234

Related Citations for PubMed (Select 15880334)

1.

Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).

Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA.

J Card Fail. 2005 May;11(4):260-9.

PMID:
15880334
2.

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA.

J Am Coll Cardiol. 2007 Jun 5;49(22):2151-9. Epub 2007 May 18.

3.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators.

JAMA. 2004 Apr 28;291(16):1963-71.

PMID:
15113814
4.

Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.

Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators.

J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056.

5.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1319-31. Epub 2007 Mar 25.

PMID:
17384437
6.

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, PiƱa I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators.

Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Erratum in: Am Heart J. 2012 May;163(5):900.

PMID:
20435194
7.

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial.

Blair JE, Pang PS, Schrier RW, Metra M, Traver B, Cook T, Campia U, Ambrosy A, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Konstam MA, Gheorghiade M; EVEREST Investigators.

Eur Heart J. 2011 Oct;32(20):2563-72. doi: 10.1093/eurheartj/ehr238. Epub 2011 Jul 23.

8.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.

JAMA. 2007 Mar 28;297(12):1332-43. Epub 2007 Mar 25.

PMID:
17384438
9.

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.

Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C; Tolvaptan Investigators.

Circulation. 2003 Jun 3;107(21):2690-6. Epub 2003 May 12.

10.

Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).

Shah AN, Mentz RJ, Gheorghiade M, Kwasny MJ, Fought AJ, Zannad F, Swedberg K, Maggioni AP, Konstam MA.

Am J Cardiol. 2012 Dec 15;110(12):1803-8. doi: 10.1016/j.amjcard.2012.08.016. Epub 2012 Sep 19.

PMID:
22999071
11.

EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.

Cavalcante JL, Khan S, Gheorghiade M.

Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1331-8. doi: 10.1586/14779072.6.10.1331.

PMID:
19018685
12.

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial.

Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M.

J Am Coll Cardiol. 2008 Nov 4;52(19):1540-5. doi: 10.1016/j.jacc.2008.08.013.

13.

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST trial investigators.

Circ Heart Fail. 2013 Jan;6(1):47-52. doi: 10.1161/CIRCHEARTFAILURE.112.970012. Epub 2012 Dec 12.

14.

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure.

Gheorghiade M, Gattis WA, Barbagelata A, Adams KF Jr, Elkayam U, Orlandi C, O'Connor CM; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure Investigators.

Am Heart J. 2003 Feb;145(2 Suppl):S51-4. No abstract available.

PMID:
12594452
15.

A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.

Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O'Brien T, Zimmer C, Orlandi C, Konstam MA.

J Card Fail. 2011 Dec;17(12):973-81. doi: 10.1016/j.cardfail.2011.08.005. Epub 2011 Sep 9.

PMID:
22123358
16.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
17.

Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.

Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M; EVEREST Investigators.

Eur Heart J. 2009 Jul;30(13):1666-73. doi: 10.1093/eurheartj/ehp144. Epub 2009 May 2.

18.

Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).

Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators.

Cardiovasc Drugs Ther. 2011 Dec;25 Suppl 1:S33-45. doi: 10.1007/s10557-011-6304-x.

PMID:
22120092
20.

Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.

Vaduganathan M, Gheorghiade M, Pang PS, Konstam MA, Zannad F, Swedberg K, Grinfeld L, Burnett JC Jr, Krasa HB, Zimmer C, Blair J, Ouyang J, Maggioni AP; EVEREST investigators.

J Cardiovasc Med (Hagerstown). 2012 Jul;13(7):415-22. doi: 10.2459/JCM.0b013e328355a740.

PMID:
22673023
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk